MA27181A1 - Derives de thiazole et d'oxazole qui modulent l'activite de ppar. - Google Patents

Derives de thiazole et d'oxazole qui modulent l'activite de ppar.

Info

Publication number
MA27181A1
MA27181A1 MA27839A MA27839A MA27181A1 MA 27181 A1 MA27181 A1 MA 27181A1 MA 27839 A MA27839 A MA 27839A MA 27839 A MA27839 A MA 27839A MA 27181 A1 MA27181 A1 MA 27181A1
Authority
MA
Morocco
Prior art keywords
ppar
activity
compounds
thiazole
modulate
Prior art date
Application number
MA27839A
Other languages
English (en)
French (fr)
Inventor
Xue-Min Cheng
Gary Frederick Filzen
Chitase Lee
Noe Ouano Erasga
Andrew George Geyer
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA27181A1 publication Critical patent/MA27181A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA27839A 2002-03-07 2004-08-30 Derives de thiazole et d'oxazole qui modulent l'activite de ppar. MA27181A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
MA27181A1 true MA27181A1 (fr) 2005-01-03

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27839A MA27181A1 (fr) 2002-03-07 2004-08-30 Derives de thiazole et d'oxazole qui modulent l'activite de ppar.

Country Status (29)

Country Link
US (1) US20030207924A1 (enExample)
EP (1) EP1482935B1 (enExample)
JP (1) JP2005528348A (enExample)
KR (1) KR20040091693A (enExample)
AP (1) AP2004003124A0 (enExample)
AR (1) AR038881A1 (enExample)
AT (1) ATE405260T1 (enExample)
AU (1) AU2003206059A1 (enExample)
BR (1) BR0308277A (enExample)
CA (1) CA2478520A1 (enExample)
CO (1) CO5601012A2 (enExample)
DE (1) DE60323060D1 (enExample)
EA (1) EA200400943A1 (enExample)
EC (1) ECSP045285A (enExample)
ES (1) ES2310650T3 (enExample)
HN (1) HN2003000090A (enExample)
IS (1) IS7377A (enExample)
MA (1) MA27181A1 (enExample)
MX (1) MXPA04007564A (enExample)
NO (1) NO20044242L (enExample)
OA (1) OA12780A (enExample)
PA (1) PA8567801A1 (enExample)
PE (1) PE20030989A1 (enExample)
PL (1) PL372969A1 (enExample)
TN (1) TNSN04168A1 (enExample)
TW (1) TW200305403A (enExample)
UY (1) UY27695A1 (enExample)
WO (1) WO2003074050A1 (enExample)
ZA (1) ZA200406068B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
BRPI0410454A (pt) * 2003-05-19 2006-06-13 Irm Llc composições e compostos imunossupressores
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
BRPI0508098A (pt) 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
ATE486055T1 (de) 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
RU2392274C2 (ru) * 2005-02-25 2010-06-20 Сеул Нэшнл Юниверсити Индастри Фаундейшн Тиазольные производные в качестве лигандов ppar-дельта и способ их получения
WO2006121223A1 (en) * 2005-05-07 2006-11-16 Heon Joong Kang Process for preparing ligands of ppardelta and the intermediate compounds for preparing the same
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
JP5052511B2 (ja) 2005-06-30 2012-10-17 ハイ ポイント ファーマシューティカルズ，エルエルシー Ｐｐａｒデルタ活性化因子としてのフェノキシ酢酸
JP5084503B2 (ja) * 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2631390C (en) 2005-12-22 2014-03-11 Per Sauerberg Phenoxy acetic acids as ppar delta activators
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
JP2009529512A (ja) 2006-03-09 2009-08-20 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規な化合物、それらの製造法、及び使用法
WO2008030520A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Heterocyclic gpr40 modulators
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
JP2010524932A (ja) 2007-04-16 2010-07-22 アムジエン・インコーポレーテツド 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸ｇｐｒ４０調節物質
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 ｇｒｐ４０ 조절제
US20090163481A1 (en) * 2007-12-13 2009-06-25 Murphy Brian J Ppar-delta ligands and methods of their use
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
ES2450567T3 (es) 2008-10-15 2014-03-25 Amgen, Inc Moduladores de GPR40 espirocíclicos
EP2540711A4 (en) * 2010-02-25 2014-01-22 Snu R&Db Foundation Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds
EP3043789B1 (en) 2013-09-09 2020-07-08 vTv Therapeutics LLC Use of a ppar-delta agonists for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
SK21099A3 (en) * 1996-08-19 2000-05-16 Japan Tobacco Inc Propionic acid derivatives and applications thereof
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1345916A1 (en) * 2000-12-20 2003-09-24 Glaxo Group Limited Substituted oxazoles and thiazoles as hppar alpha agonists
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
SK14922003A3 (sk) * 2001-06-07 2005-04-01 Eli Lilly And Company Modulátory receptorov aktivovaných proliferátormi peroxizómov (PPAR)

Also Published As

Publication number Publication date
JP2005528348A (ja) 2005-09-22
EA200400943A1 (ru) 2005-02-24
ES2310650T3 (es) 2009-01-16
ECSP045285A (es) 2004-10-26
CO5601012A2 (es) 2006-01-31
PE20030989A1 (es) 2003-11-29
MXPA04007564A (es) 2004-11-10
UY27695A1 (es) 2003-10-31
OA12780A (en) 2006-07-07
EP1482935B1 (en) 2008-08-20
NO20044242L (no) 2004-10-06
TNSN04168A1 (fr) 2007-03-12
BR0308277A (pt) 2004-12-28
CA2478520A1 (en) 2003-09-12
KR20040091693A (ko) 2004-10-28
AU2003206059A1 (en) 2003-09-16
PA8567801A1 (es) 2003-11-12
PL372969A1 (en) 2005-08-08
US20030207924A1 (en) 2003-11-06
AR038881A1 (es) 2005-02-02
EP1482935A1 (en) 2004-12-08
DE60323060D1 (de) 2008-10-02
ATE405260T1 (de) 2008-09-15
IS7377A (is) 2004-07-29
WO2003074050A1 (en) 2003-09-12
ZA200406068B (en) 2005-09-06
TW200305403A (en) 2003-11-01
HN2003000090A (es) 2004-05-05
AP2004003124A0 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
MA27181A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar.
MA27182A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar.
MA27189A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA26688A1 (fr) 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
AU1850801A (en) The combination of a serotonin reuptake inhibitor and irindalone
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
FR08C0004I2 (fr) Composition orale d' une dose pour une libération prolongée
MA26954A1 (fr) ALPHA-ARYLETHANOLAMINES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS BeTA3-ADRENERGIQUES
MA26997A1 (fr) Derives de 3-(4-amidopyrrole-2-ylmethylidene)-2-indolinone utilisables comme inhibiteurs de proteine-kinases
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA27135A1 (fr) Agents antidiabetiques oraux
PT1003725E (pt) Fungicidas de fluoropirazoldifenilamidas
DZ2752A1 (fr) Composés et compositions pharmaceutiques pour le traitement du paludisme.
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA27141A1 (fr) DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
SE9903997D0 (sv) New compounds
IL152337A0 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
WO1999012570A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.